On March 6, 2013 Vernalis plc and Servier, France’s largest privately-owned pharmaceutical company, reported the further extension of their ongoing oncology collaboration initiated in May 2007 (Press release, Servier, JUN 3, 2013, View Source [SID:1234508823]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is the first of three collaborations between Vernalis and Servier and focuses on multiple undisclosed oncology targets. It was initially extended in October 2011 and is now extended for a further two years.

Ian Garland, CEO of Vernalis, commented "We are delighted by this news which reflects Servier’s continued endorsement of our joint achievements over the past few years."

Servier’s head of research, Bernard Marchand, said: "this 2-year extension highlights our commitment to cancer research through innovative drug discovery platforms."